|
|
Volumn 26, Issue 4, 2008, Pages 361-363
|
|
Can 'double blockbuster' strengthen Amgen's backbone?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACE 011;
ALENDRONIC ACID;
AMG 785;
APRELA;
AROMATASE INHIBITOR;
ARZOXIFENE;
BA 058;
BALICATIB;
BAZEDOXIFENE;
BAZEDOXIFENE PLUS CONJUGATED ESTROGEN;
DENOSUMAB;
FABLYN;
IBANDRONIC ACID;
IMMUNOGLOBULIN F(AB) FRAGMENT;
LASOFOXIFENE;
MIV 701;
MK 0822;
NB S101;
ODANACATIB;
PARATHYROID HORMONE[1-34];
RALOXIFENE;
RECLAST;
RECOMBINANT ERYTHROPOIETIN;
RECOMBINANT PARATHYROID HORMONE RELEASING PEPTIDE;
RELACATIB;
RISEDRONIC ACID;
STRONTIUM MALONATE;
STRONTIUM RANELATE;
UNCLASSIFIED DRUG;
ZOLEDRONIC ACID;
BONE DEFECT;
BONE DENSITY;
BONE TURNOVER;
BREAST CANCER;
CANCER PATIENT;
DRUG INDUSTRY;
DRUG MANUFACTURE;
FRACTURE;
HIP FRACTURE;
HUMAN;
MORBIDITY;
MORTALITY;
NOTE;
OSSIFICATION;
OSTEOCLAST;
OSTEOLYSIS;
OSTEOPOROSIS;
OUTCOME ASSESSMENT;
PAGET BONE DISEASE;
PRIORITY JOURNAL;
RISK ASSESSMENT;
VERTEBRA FRACTURE;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG INDUSTRY;
HUMANS;
OSTEOPOROSIS;
UNITED STATES;
|
|
EID: 41849139001
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0408-361 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|
